MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

164.34
+4.00
+2.49%
After Hours: 165.00 +0.66 +0.40% 19:48 03/05 EST
OPEN
161.47
PREV CLOSE
160.34
HIGH
164.77
LOW
159.02
VOLUME
502.20K
TURNOVER
--
52 WEEK HIGH
181.14
52 WEEK LOW
75.58
MARKET CAP
7.32B
P/E (TTM)
14.22
1D
5D
1M
3M
1Y
5Y
Global Pulmonary Arterial Hypertension (PAH) Market Outlook, Industry Analysis and Prospect 2016 -2027
Mar 04, 2021 (Heraldkeepers) -- COMTEX_382121700/2582/2021-03-04T04:27:54 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 3d ago
Pulmonary Arterial Hypertension (PAH) Market Analysis By Industry Growth, Size, Share, Demand, Trends and Research Report
Japan, Japan, Thu, 04 Mar 2021 02:33:10 / Comserve Inc. / -- Pulmonary Arterial Hypertension (PAH) Market :Global Size, Share, Trends, Forecast, Growth, Key...
Comserve · 3d ago
United Therapeutics slips after the decision to discontinue Trevyent development
United Therapeutics ([[UTHR]] -2.0%) is trading lower today after announcing its decision to discontinue the development of Trevyent (Treprostinil) due to written feedback received from the FDA in late February.The FDA comments
Seekingalpha · 4d ago
Looking Into United Therapeutics's Return On Capital Employed
United Therapeutics (NASDAQ:UTHR) posted a 69.99% decrease in earnings from Q3. Sales, however, increased by 1.26% over the previous quarter to $384.90 million. Despite the increase in sales this quarter, the decrease in earnings may suggest United Therape...
Benzinga · 4d ago
Sector Update: Health Care
MT Newswires · 4d ago
United Therapeutics Scraps Trevyent Development, To Book Impairment Charge in Q1
MT Newswires · 4d ago
United Therapeutics Pulls Plug On Trevyent Development
Based on the FDA’s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has 
Benzinga · 4d ago
8-K: UNITED THERAPEUTICS Corp
(EDGAR Online via COMTEX) -- 0001082554 false 0001082554 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of UTHR. Analyze the recent business situations of Utd Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UTHR stock price target is 196.00 with a high estimate of 275.00 and a low estimate of 115.00.
EPS
Institutional Holdings
Institutions: 604
Institutional Holdings: 46.60M
% Owned: 104.62%
Shares Outstanding: 44.54M
TypeInstitutionsShares
Increased
99
1.87M
New
107
3.18M
Decreased
138
4.42M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Director
Martine Rothblatt
President/Chief Operating Officer
Michael Benkowitz
Vice Chairman/Lead Director/Independent Director
Christopher Patusky
Chief Financial Officer/Treasurer
James Edgemond
Executive Vice President/General Counsel/Secretary
Paul Mahon
Director
Linda Maxwell
Independent Director
Christopher Causey
Independent Director
Raymond Dwek
Independent Director
Richard Giltner
Independent Director
Katherine Klein
Independent Director
Raymond Kurzweil
Independent Director
Nilda Mesa
Independent Director
Judy Olian
Independent Director
Louis Sullivan
Independent Director
Tommy Thompson
No Data
About UTHR
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.